Description

BSE lists 18,19,21,827 equity shares of Viyash Scientific Ltd effective January 29, 2026, issued pursuant to composite scheme of amalgamation involving multiple entities.

Summary

BSE has approved the listing of 18,19,21,827 equity shares of Rs. 2/- each of Viyash Scientific Ltd (formerly Sequent Scientific Ltd, Scrip Code: 512529) effective from January 29, 2026. These shares were issued pursuant to a composite scheme of amalgamation involving Sequent Scientific Limited and nine other entities including Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited, and Sequent Research Limited. The scheme was approved under Sections 230 to 232 of the Companies Act, 2013.

Key Points

  • Total of 18,19,21,827 equity shares of Rs. 2/- each to be listed
  • Shares issued under composite scheme of amalgamation involving 10 entities
  • New shares rank pari-passu with existing equity shares
  • ISIN: INE807F01027
  • Distinctive Numbers: 254112650 to 436034476
  • Date of Allotment: December 16, 2025
  • Company formerly known as Sequent Scientific Ltd, now Viyash Scientific Ltd
  • Scrip Code: 512529

Regulatory Changes

No new regulatory changes introduced. This circular implements the outcome of a composite scheme of amalgamation approved under the Companies Act, 2013.

Compliance Requirements

  • Market participants must note the listing of new securities for trading purposes
  • The newly listed shares are eligible for trading with effect from January 29, 2026
  • Clarifications can be sought by contacting BSE at 022-2272 5271/5878

Important Dates

  • Allotment Date: December 16, 2025
  • Trading Commencement Date: January 29, 2026 (Thursday)
  • Circular Issue Date: January 28, 2026

Impact Assessment

The listing represents a significant corporate restructuring involving the amalgamation of 10 companies into Viyash Scientific Ltd. The issuance of approximately 18.19 crore shares substantially increases the company’s equity base. Since the shares rank pari-passu with existing shares, existing shareholders’ rights remain protected. The amalgamation consolidates operations across multiple pharmaceutical and life sciences entities, potentially creating operational synergies. Market participants should note the substantial increase in share capital when evaluating trading volumes and liquidity. The name change from Sequent Scientific Ltd to Viyash Scientific Ltd reflects the post-merger identity.

Impact Justification

Significant corporate restructuring involving amalgamation of 10 entities with substantial equity issuance, but limited immediate trading impact as shares rank pari-passu with existing shares.